Efficacy of edaravone dexborneol combined with alteplase in treatment of acute ischemic stroke
- VernacularTitle:依达拉奉右莰醇联合阿替普酶治疗急性缺血性脑卒中的疗效观察
- Author:
Chunying LI
1
;
Ying JIN
1
Author Information
- Publication Type:Journal Article
- Keywords: Edaravone dexborneol; Alteplase; Acute ischemic stroke
- From: Journal of Apoplexy and Nervous Diseases 2023;40(10):936-938
- CountryChina
- Language:Chinese
- Abstract: Objective To investigate the efficacy and safety of edaravone dexborneol combined with alteplase in the treatment of acute ischemic stroke （AIS）. Methods The data were collected from 124 patients with AIS who were admitted to our hospital from November 2020 to April 2022. The patients were randomly divided into experimental group （intravenous thrombolysis with alteplase + treatment with edaravone dexborneol） and control group （intravenous thrombolysis with alteplase）， and the two groups were compared for efficacy. Results The overall response rate in the experimental group was significantly higher than that in the control group （82.3% vs 64.5%， P < 0.05）. The National Institutes of Health Stroke Scale scores at different stages after thrombolysis were significantly lower in the experimental group （5.40 ± 3.82， 4.14 ± 3.44， and 0.57 ± 0.99） than in the control group （P < 0.05）. No adverse drug reactions were observed in the two groups during the treatment. Conclusion Edaravone dexborneol combined with alteplase has definite clinical efficacy in the treatment of AIS.
- Full text:2024061322093930410依达拉奉右莰醇联合阿替普酶治疗急性缺血性脑卒中的疗效观察.pdf
